Olivier Van Der Meeren

6PUBLICATIONS
30CO-AUTHORS
Innate immunityPacific Peoples health promotionPreventative health careEpidemiological methods
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 20, 2024
Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

Vimla Naicker, Fatima Laher, Linda-Gail Bekker

|Mar 19, 2024
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial.

Zoe Moodie, Erica Andersen-Nissen, Nicole Grunenberg

|Mar 24, 2021
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.

Glenda E Gray, Linda-Gail Bekker, Fatima Laher

|Feb 25, 2020
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.

Fatima Laher, Zoe Moodie, Kristen W Cohen

|Oct 30, 2019
Final Analysis of a Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Dereck R Tait, Mark Hatherill, Olivier Van Der Meeren

|Oct 04, 2018
Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis.

Olivier Van Der Meeren, Mark Hatherill, Videlis Nduba

Pageof 1

Frequent Collaborators

3 joint publications

Fatima Laher

3 joint publications

Zoe Moodie

3 joint publications

Kathryn Mngadi

3 joint publications

Lawrence Corey